IL302683A - Compositions and methods for treating solid cancer - Google Patents

Compositions and methods for treating solid cancer

Info

Publication number
IL302683A
IL302683A IL302683A IL30268323A IL302683A IL 302683 A IL302683 A IL 302683A IL 302683 A IL302683 A IL 302683A IL 30268323 A IL30268323 A IL 30268323A IL 302683 A IL302683 A IL 302683A
Authority
IL
Israel
Prior art keywords
cancer
peroxide
haloperoxidase
oxidase
composition
Prior art date
Application number
IL302683A
Other languages
English (en)
Hebrew (he)
Original Assignee
Exoxemis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exoxemis Inc filed Critical Exoxemis Inc
Publication of IL302683A publication Critical patent/IL302683A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/327—Peroxy compounds, e.g. hydroperoxides, peroxides, peroxyacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/20—Elemental chlorine; Inorganic compounds releasing chlorine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/40—Peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/443—Oxidoreductases (1) acting on CH-OH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
    • C12Y111/01—Peroxidases (1.11.1)
    • C12Y111/01007—Peroxidase (1.11.1.7), i.e. horseradish-peroxidase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
    • C12Y111/01—Peroxidases (1.11.1)
    • C12Y111/0101—Chloride peroxidase (1.11.1.10)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
    • C12Y111/02—Oxidoreductases acting on a peroxide as acceptor (1.11) with H2O2 as acceptor, one oxygen atom of which is incorporated into the product (1.11.2)
    • C12Y111/02002—Myeloperoxidase (1.11.2.2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL302683A 2020-11-11 2021-10-01 Compositions and methods for treating solid cancer IL302683A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063112447P 2020-11-11 2020-11-11
PCT/US2021/053155 WO2022103515A1 (en) 2020-11-11 2021-10-01 Compositions and methods for treating solid cancer

Publications (1)

Publication Number Publication Date
IL302683A true IL302683A (en) 2023-07-01

Family

ID=81601629

Family Applications (1)

Application Number Title Priority Date Filing Date
IL302683A IL302683A (en) 2020-11-11 2021-10-01 Compositions and methods for treating solid cancer

Country Status (10)

Country Link
US (1) US20230398190A1 (https=)
EP (1) EP4243835A4 (https=)
JP (1) JP2023548406A (https=)
KR (1) KR20230106646A (https=)
CN (1) CN116710121A (https=)
AU (1) AU2021379542A1 (https=)
CA (1) CA3196357A1 (https=)
IL (1) IL302683A (https=)
MX (1) MX2023005171A (https=)
WO (1) WO2022103515A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250332226A1 (en) * 2022-04-13 2025-10-30 Exoxemis, Inc. Compositions and methods for treating solid cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4486408A (en) * 1981-04-07 1984-12-04 Kiel Johnathan L Insoluble crosslinked cytotoxic oxidase-peroxidase system
WO2007103525A2 (en) * 2006-03-09 2007-09-13 Glanbia Nutritionals (Ireland) Limited Cationic whey protein composition
WO2013009910A2 (en) * 2011-07-11 2013-01-17 Exoxemis, Inc. Eosinophil peroxidase compositions and methods of their use
EP4548978A3 (en) * 2015-01-29 2025-08-06 Oxyrase, Inc. Methods for inhibiting tumor growth
US10213448B2 (en) * 2016-03-25 2019-02-26 Novazoi Theranostics Ethanolamine-based lipid biosynthetic compounds, method of making and use thereof
US20190271703A1 (en) * 2016-10-26 2019-09-05 Duke University Biomarkers and treatments for metastatic cancer

Also Published As

Publication number Publication date
US20230398190A1 (en) 2023-12-14
WO2022103515A1 (en) 2022-05-19
KR20230106646A (ko) 2023-07-13
CA3196357A1 (en) 2022-05-19
EP4243835A1 (en) 2023-09-20
AU2021379542A1 (en) 2023-06-08
JP2023548406A (ja) 2023-11-16
AU2021379542A9 (en) 2024-09-05
MX2023005171A (es) 2023-06-26
EP4243835A4 (en) 2024-08-28
CN116710121A (zh) 2023-09-05

Similar Documents

Publication Publication Date Title
Glazer et al. Bioengineered human arginase I with enhanced activity and stability controls hepatocellular and pancreatic carcinoma xenografts
CN1582156A (zh) 眼新血管疾病的治疗方法
CN1213742C (zh) 炎症的药物控制
CN118785919A (zh) 用于癌症治疗的精氨酸酶和精氨基琥珀酸合酶
Okada et al. Prevention of inflammation-mediated acquisition of metastatic properties of benign mouse fibrosarcoma cells by administration of an orally available superoxide dismutase
US20240277791A1 (en) Device and methods for acne therapeutics: antibacterial bacteriophages and engineered lysins
IL302683A (en) Compositions and methods for treating solid cancer
CN113144172B (zh) 一种含有万古霉素、ir780与携氧全氟己烷的脂质体的制备方法
Xu et al. “Three musketeers” enhances photodynamic effects by reducing tumor reactive oxygen species resistance
KR20040063943A (ko) 안과 질환 및 질병의 치료를 위한 과산화물 디스뮤타제모방체
US20250332226A1 (en) Compositions and methods for treating solid cancer
WO2024017192A1 (zh) 包含血细胞的药物递送系统
CN115778984A (zh) 一种诱导移植免疫耐受的方法、应用和移植耐受性动物模型
CN102485272A (zh) 重组人Prx-6蛋白在治疗烧烫伤方面的用途
Clarke et al. Sustained lung activity of a novel chimeric protein, SOD2/3, after intratracheal administration
HK40098212A (zh) 用於治疗实体癌的组合物和方法
CN117045680B (zh) 促进肝脏再生的干细胞制剂及其制备方法
Skrzycki et al. Superoxide dismutase as a potential therapeutic agent
Guo et al. Living bacterial reactor potently activates tumor immunogenic ferroptosis via cysteine depletion and photothermal therapy
Li et al. A syringe‐focused ultrasound device for simultaneous injection of DNA and gene transfer
AU2024296221A1 (en) Combination of a hb-egf inhibitor and a corticosteroid agent for the treatment of kidney diseases associated with activation of the hb-egf/egfr pathway
TW202327566A (zh) 包含藻褐素及小分子褐藻醣膠之組合物用於製備治療或改善慢性腎病之醫藥品的用途及包含藻褐素、小分子褐藻醣膠及左旋肉鹼之組合物及包含其的醫藥品
Braun Quatuor pour la flûte, violon, viola et violoncelle, oeuv. VI
US20060223876A1 (en) Indoloquinone Tumor Radiation Sensitization
Varghese Salivary gland radiation protection